MedTrace Logo

Maintenance Boosted Lopinavir Monotherapy Following Salvage Protease-inhibitor (PI) Based Regimen in HIV With Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI) Based Regimen Failure

NCT01189695 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2013-05-13

No results posted yet for this study

Summary

The objective of this study is to determine efficacy of ritonavir-boosted lopinavir monotherapy as a maintenance regimen in HIV-1-infected patients who previously failed Non-nucleoside reverse transcriptase inhibitors (NNRTI) based regimens and currently received salvage protease-inhibitor (PI) based regimens.

Conditions

  • HIV
  • AIDS
  • Lopinavir
  • Treatment Failure

Interventions

DRUG

Ritonavir-boosted lopinavir

Lopinavir/ritonavir 200/50 mg every 12 hours

DRUG

optimized background regimens (OBRs)

Optimized background regimens such as NRTIs, etravirine or raltegravir

Sponsors & Collaborators

  • Department of Disease Control, Thailand

    collaborator UNKNOWN

  • Bamrasnaradura Infectious Diseases Institute

    lead OTHER_GOV

Principal Investigators

  • Krittaecho Siripassorn, MD · Bamrasnaradura Infectious Diseases Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2012-12-31
Completion
2013-01-31

Countries

  • Thailand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01189695 on ClinicalTrials.gov